Biodexa Pharmaceuticals PLC (BDRX) News & EventsBDRXNews & EventsBiodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals Sets Pricing for $0.8M Registered Offering

Biodexa Pharmaceuticals announced the pricing of a $0.8M registered offering, a $1M concurrent private placement, and a $1.7M warrant inducement utilizing existing share capital authorities. The Registered Offering consists of 282,952 American depositary shares at an offering price of $2.85 per ADS. The Private Offering consists of pre-funded warrants to purchase 350,877 ADSs at a combined offering price of $2.8499 per pre-funded warrant. In consideration for the immediate exercise of existing warrants for cash, the company agreed to reduce the exercise price of the Existing Warrants to $2.85 and, subject to shareholder approval, issue new unregistered Series O warrants to purchase an aggregate of 1,219,512 ADSs. The offerings are expected to close on or about July 1. The aggregate gross proceeds to the company, before deducting placement agent fees and other offering expenses, are expected to be approximately $3.5M. Maxim Group is acting as the sole placement agent and warrant inducement agent for the offerings.

Biodexa Partners with Syngene for MTX240 Production

Biodexa Pharmaceuticals announced that it has partnered with Syngene for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.

Tanner Pharma Partners with Biodexa to Promote eRapa

Tanner Pharma Group and Biodexa Pharmaceuticals have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis, FAP, through an Early Access / Named Patient Program. Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa in countries where it is not currently available, allowing clinicians treating FAP patients to prescribe this investigational therapy outside of a clinical trial for the first time.